Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Cureus ; 14(2): e22342, 2022 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-35371792

RESUMO

Introduction As we care for patients during the coronavirus pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it is important to learn and analyze the health outcomes for HIV-positive patients who have been infected with COVID-19. The clinical course and outcome of COVID-19 among patients with HIV-1 infection are still unknown and novel. Methods This is a retrospective cohort study of 34 HIV-positive patients who are diagnosed with COVID-19. The following basic demographic, clinical, and laboratory test information were collected for each patient: age, race/ethnicity, gender, CD4/viral load count before and after COVID-19 diagnosis, clinical symptoms, hospitalizations, antiretroviral medications, and comorbidities. These data were collected from the electronic health record (EHR) and recorded in the study database. Results The mean (interquartile range (IQR)) HIV viral load (RNA PCR) after COVID-19 infection was 37,170 (<20-167) copies/mL compared to 25,730 (<20-100) copies/mL before COVID-19 infection. The mean (IQR) CD4+ lymphocyte count prior to and after COVID-19 infection was 583 (101-1139) and 477 (167-821) cells/mm3, respectively. Hypertension (n = 20) was the most prevalent comorbidity found in the cohort of HIV-positive patients. Patients with HIV RNA < 20 copies/mL prior to and after COVID-19 infection were 27 (79.3%) and 17 (73.7%), respectively. Conclusion As the pandemic situation keeps on evolving, there will be new findings on how people living with HIV might be affected by SARS-CoV-2. Our findings highlight the importance of larger sample size studies to better understand the management of HIV-positive patients in a pandemic situation.

2.
Cytotherapy ; 11(2): 238-44, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19241194

RESUMO

BACKGROUND AIMS: Chronic lymphocytic leukemia (CLL) is an indolent disease. It is currently recommended that patients with CLL stages 0 and I follow a watchful waiting strategy. These patients are, therefore, a suitable group for testing immunotherapeutic approaches to avoid problems of immunosuppression as a result of disease progression and chemotherapy. In this study, we investigated the expression of SEMG-1 in early CLL to determine the suitability of SEMG-1 as a target for further development of tumor vaccines for early CLL. METHODS: A combination of reverse transcriptase (RT)-polymerase chain reaction (PCR) and immunocytochemistry was used to evaluate the expression of SEMG-1 in early CLL. The results were correlated with Zap 70 expression. Recombinant SEMG-1 protein was used in an enzyme-linked immunosorbent assay (ELISA) to determine the presence of SEMG-1 antibodies (Ab) in serum from these patients. RESULTS: The SEMG-1 gene was expressed in 19/41 (46%) patients with early CLL. Gene expression was associated with protein synthesis in CLL cells. Protein expression, however, was heterogeneous within individual patients. Only transcripts encoding the SEMG-1(50) variant and not SEMG-1(43) were detected. SEMG-1(50) was expressed irrespective of the Zap 70 status. High-titer SEMG-1 IgG but not IgM Ab were detected in some of these patients, suggesting that SEMG-1-reactive immune responses are intact within the immune repertoire of early CLL patients. CONCLUSIONS: SEMG-1 is expressed in nearly half of patients with early CLL and may be a target for further investigations into its use for immunotherapy of early CLL.


Assuntos
Antígenos de Neoplasias/metabolismo , Biomarcadores Tumorais/metabolismo , Leucemia Linfocítica Crônica de Células B/imunologia , Proteínas Secretadas pela Vesícula Seminal/metabolismo , Formação de Anticorpos , Antígenos de Neoplasias/genética , Antígenos de Neoplasias/imunologia , Biomarcadores Tumorais/genética , Biomarcadores Tumorais/imunologia , Vacinas Anticâncer , Ensaio de Imunoadsorção Enzimática , Regulação Neoplásica da Expressão Gênica , Humanos , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Imuno-Histoquímica , Leucemia Linfocítica Crônica de Células B/sangue , Leucemia Linfocítica Crônica de Células B/metabolismo , Leucemia Linfocítica Crônica de Células B/prevenção & controle , Estadiamento de Neoplasias , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Proteínas Secretadas pela Vesícula Seminal/genética , Proteínas Secretadas pela Vesícula Seminal/imunologia , Proteína-Tirosina Quinase ZAP-70/genética , Proteína-Tirosina Quinase ZAP-70/imunologia , Proteína-Tirosina Quinase ZAP-70/metabolismo
3.
Br J Haematol ; 144(5): 660-6, 2009 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19036087

RESUMO

Early chronic lymphocytic leukaemia (CLL) is an ideal disease for immunotherapy. We previously showed that SEMG 1 is a cancer-testis (CT) antigen in CLL. In this study, SEMG 1 was applied as the bait in a yeast two-hybrid system of a testicular cDNA library. Seven clones were isolated and Protamine (Prm) 1 was identified as a novel CT antigen in early CLL. PRM1 transcripts were detected in 11/41 (26.8%) patients. Prm 1 protein was also expressed but heterogeneously within individual patients. Of the 11 patients expressing Prm 1, four expressed Zap 70 protein and seven did not. These results, therefore, indicate that Prm 1 could potentially be a suitable target for the design of tumour vaccine for patients with early CLL, including for those with poor risk CLL. High titres of Prm 1 IgG antibodies could be detected in 20 of these 41 CLL patients but not in any of the 20 healthy donors (P = 0.0001), suggesting the presence of Prm 1-reactive immune responses within the immune repertoire of patients with early CLL. Further work is warranted, especially in approaches to upregulate Prm 1 expression, and to determine the role of Prm 1 as an immunotherapeutic target for early CLL.


Assuntos
Biomarcadores Tumorais/análise , Leucemia Linfocítica Crônica de Células B/imunologia , Protaminas/análise , Anticorpos/sangue , Linfócitos B/imunologia , Biomarcadores Tumorais/imunologia , Vacinas Anticâncer , Estudos de Casos e Controles , Detecção Precoce de Câncer , Ensaio de Imunoadsorção Enzimática/métodos , Biblioteca Gênica , Humanos , Imunoglobulina G/sangue , Imuno-Histoquímica , Imunoterapia , Leucemia Linfocítica Crônica de Células B/sangue , Masculino , Protaminas/imunologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos , Proteínas Secretadas pela Vesícula Seminal/análise , Testículo/imunologia , Técnicas do Sistema de Duplo-Híbrido , Proteína-Tirosina Quinase ZAP-70/análise
4.
Int J Cancer ; 121(7): 1507-11, 2007 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-17551920

RESUMO

Since most intracellular proteins are expressed with their ligands, ligands of cancer-testis (CT) antigens may also be CT in their distribution. Applying Sperm protein 17 (Sp17) as the bait in a yeast 2-hybrid system of a testicular cDNA library, 17 interacting clones were isolated and all encoded Ropporin, a spermatogenic cell-specific protein that serves as an anchoring protein for the A-kinase anchoring protein, AKAP110. Ropporin showed a very restricted normal tissue gene expression, detected only in testis and fetal liver. Ropporin mRNA could also be detected in tumor cells from patients with multiple myeloma, chronic lymphocytic leukemia and acute myeloid leukemia. Interestingly, expression of Sp17 did not necessarily predict for the expression of Ropporin suggesting that their coexpression in these tumor cells was random rather than coordinated. Ropporin gene expression in tumor cells is associated with the presence of high titer IgG antibodies against Ropporin, suggesting the in vivo translation of the mRNA into protein and the immunogenicity of the protein to the autologous hosts. Using a CT antigen as the bait in a yeast 2-hybrid system may, therefore, identify novel tumor antigen. Our results also suggest that Ropporin is a novel CT antigen in hematologic malignancies.


Assuntos
Antígenos de Neoplasias/metabolismo , Antígenos de Superfície/metabolismo , Proteínas de Transporte/metabolismo , Neoplasias Hematológicas/metabolismo , Proteínas de Membrana/metabolismo , Técnicas do Sistema de Duplo-Híbrido , Proteínas rho de Ligação ao GTP/metabolismo , Proteínas Adaptadoras de Transdução de Sinal/metabolismo , Antígenos de Neoplasias/genética , Antígenos de Superfície/genética , Western Blotting , Proteínas de Ligação a Calmodulina , Proteínas de Transporte/genética , Ensaio de Imunoadsorção Enzimática , Regulação Neoplásica da Expressão Gênica , Neoplasias Hematológicas/sangue , Neoplasias Hematológicas/genética , Humanos , Imunoglobulina G/sangue , Imunoglobulina G/imunologia , Masculino , Proteínas de Membrana/genética , Proteínas de Membrana/imunologia , Ligação Proteica , Proteínas Recombinantes/metabolismo , Espermatozoides/metabolismo , Testículo/metabolismo , Leveduras/genética , Proteínas rho de Ligação ao GTP/genética , Proteínas rho de Ligação ao GTP/imunologia
5.
Br J Haematol ; 136(6): 769-76, 2007 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-17223912

RESUMO

Immunotherapy is an attractive therapeutic option for patients with haematological malignancies. Until recently, the progress in the development of tumour vaccines for haematological malignancies had been slow due to the lack of suitable targets. Cancer-testis (CT) antigens are potentially suitable molecules for tumour vaccines of haematological malignancies because of their high immunogenicity in vivo and their relatively restricted normal tissue distribution. This review evaluates the properties and potential functions of CT antigens. We discuss the expression of CT antigens in patient with haematological malignancies and provide evidence in support of their immunogenicity in vivo in these patients. We also address the role of 'epigenetic' regulation of CT antigens in haematological malignancies and how hypomethylating agents could induce the expression of some of these antigens in tumour cells to overcome the problem of heterogeneity of expression of the antigen within individual tumour specimens. Data implicating the interaction of the promoter genes of some of these CT antigens with the MeCP2 protein also suggest the potential role of the histone deacetylase inhibitors in inducing antigen expression in tumour cells. Finally, we discuss the direction of future research in advancing the development of tumour vaccines for haematological malignancies.


Assuntos
Antígenos de Neoplasias/administração & dosagem , Vacinas Anticâncer/administração & dosagem , Neoplasias Hematológicas/terapia , Imunoterapia Ativa/métodos , Testículo/imunologia , Antígenos de Neoplasias/genética , Antígenos de Neoplasias/imunologia , Metilação de DNA/efeitos dos fármacos , Células Dendríticas/imunologia , Regulação Neoplásica da Expressão Gênica , Neoplasias Hematológicas/imunologia , Humanos , Interleucinas/administração & dosagem , Interleucinas/imunologia , Masculino
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...